



MEMORANDUM

DT&T publishes three-year real-world study demonstrating sustained MiniMed 780G glycemic outcomes in youth with T1D – July 20, 2026

MiniMed 780G maintained international glycemic targets over three years; increasing reliance on automated corrections underscores need for ongoing education

DT&T published a real-world study last week titled, “[Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study](#),” by Dr. [Bruno Bombaci](#) (University of Messina, Italy), Prof. [Fortunato Lombardo](#) (University of Messina, Italy), Prof. [Marta Bassi](#) (University of Genoa, Italy) et al. In this longitudinal analysis, researchers evaluated glycemic outcomes over three years following initiation of MiniMed 780G in children and adolescents with T1D (n=359) across 20 Italian pediatric diabetes centers. Notably, participants maintained excellent glycemic outcomes throughout follow-up, with median TIR remained at 74%-75%, median Time above Range (TAR; >180 mg/dL) of 24%, and median TAR (>250 mg/dL) of only 4% after three years - well within international consensus targets. Mean A1c levels also remained stable at 6.9%-7.0%.

However, researchers observed slight declines in TIR (75% to 74%) and Time in Tight Range (TITR; 50% to 48%), accompanied by increasing reliance on automated correction boluses and fewer user-initiated meal boluses and carbohydrate entries over time. Higher SmartGuard use, optimal system settings, and fewer automated correction boluses independently predicted achieving TITR $\geq$ 50% at three years. The authors concluded that while MiniMed 780G provides durable long-term glycemic outcomes, sustained outcomes will require ongoing education, proactive device setting optimization, and continued user engagement.

--by Riya Chatterjee, Monica Oxenreiter, and Kelly Close